INSM analyst estimates
Insmed (INSM) analyst ratings, the average price target and its range, and every firm's latest call.
INSM analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 29, 2026 | Mizuho Securities | Insmed price target lowered to $154 from $195 at Mizuho | $154.00 |
| Oct 29, 2026 | Stifel Nicolaus | Insmed (INSM) PT Lowered to $195 at Stifel | $195.00 |
| Oct 21, 2026 | Morgan Stanley | Insmed price target lowered to $213 from $218 at Morgan Stanley | $213.00 |
| Oct 20, 2026 | Raymond James | Insmed price target lowered to $173 from $187 at Raymond James | $173.00 |
| Oct 12, 2026 | Raymond James | Insmed (INSM) PT Lowered to $207 at BofA Securities | $207.00 |
| Sep 30, 2026 | Barclays | Insmed price target lowered to $207 from $237 at Barclays | $207.00 |
| Sep 24, 2026 | Goldman Sachs | Insmed resumed with a Buy at Goldman Sachs | $188.00 |
| Sep 15, 2026 | Roth Capital | Insmed price target lowered to $198 from $212 at Roth Capital | $198.00 |
| Aug 10, 2026 | Truist Financial | Insmed price target raised to $195 from $185 at Truist | $195.00 |
| Aug 7, 2026 | Wells Fargo | Insmed price target raised to $169 from $161 at Wells Fargo | $169.00 |
| Aug 7, 2026 | UBS | Insmed price target raised to $172 from $166 at UBS | $172.00 |
| Aug 7, 2026 | Guggenheim | Insmed price target lowered to $205 from $207 at Guggenheim | $205.00 |
| Aug 7, 2026 | Evercore ISI | Insmed price target raised to $170 from $160 at Evercore ISI | $170.00 |
| Aug 7, 2026 | Morgan Stanley | Insmed price target raised to $218 from $212 at Morgan Stanley | $218.00 |
| Aug 6, 2026 | Jefferies | Insmed price target raised to $175 from $160 at Jefferies | $175.00 |
- 20 firms rate INSM: 19 buy, 1 hold, 0 sell.
- The average price target is $185.69 from 13 analysts, from $154.00 to $213.00.
Updated 2026-11-02 23:11 UTC